Patients who were drug-nave ( HbA1c 7.0 % and 9.0 % ) , or on background glucose-lowering therapy ( HbA1c 7.0 % and 10.0 % ) , and were at high risk of CV events , were randomized ( 1:1:1 ) and treated with empagliflozin 10 mg , empagliflozin 25 mg , or placebo ( double blind , double dummy ) superimposed upon the standard of care .